

Case Details Report

Date and Time: 18 Jun 2018 01:33:03 a.m.

www.iponz.govt.nz

INTERNATIONAL: +64 3 962 2607

NATIONAL: 0508 4 IPONZ
(0508 447 669)

Search Criteria:

Title/Office Title/Abstract: CD80

Patent Number (11): 630535

Status: Granted

Application type: National Entry PCT

Technology group: Chemical

Patent Date: 13 Mar 2014

National Phase Entry Date: 09 Sep 2014

Lapse Date: 13 Mar 2019

Complete Specification Filing Date: 13 Mar 2014

PCT Publication Number: WO/2014/151634

Application made under: Patents Act 1953

Submitted Date: 09 Sep 2014

Filing Date (22): 13 Mar 2014

Acceptance Date: 15 Apr 2017

Postpone Acceptance period: 18

Grant Date: 01 Aug 2017

Published Date: 28 Apr 2017

Expiry Date: 13 Mar 2034

Renewal Due Date: 13 Mar 2019

Expedited Examination Requested: No

Under Proceeding: No

PCT Application Number: PCT/US2014/026138

Granted as Patent of addition: No


Patent Title: MACROCYCLIC INHIBITORS OF THE PD-1/PD-L1 AND CD80(B7-1)/PD-L1 PROTEIN/PROTEIN INTERACTIONS

Declaration: We are the applicants for the PCT international application

We declare the first and true inventor(s) of the invention disclosed in the complete specification filed with the present application are as listed. If you do not make this declaration you will have to submit a Declaration of Inventorship in the future before your application can be accepted.

Abstract: The present disclosure provides novel macrocyclic peptides of formula (I), which inhibit the PD-1/PD-L1 and PD-L1/CD80 protein/protein interaction, and thus are useful for the amelioration of various diseases, including cancer and infectious diseases.

Abstract Drawing:



Patent Specifications:

Number: 630535

Title	Filing Date	Publication Date	Status
MACROCYCLIC INHIBITORS OF THE PD-1/PD-L1 AND CD80(B7-1)/PD-L1 PROTEIN/PROTEIN INTERACTIONS	11 Nov 2016	25 Aug 2017	Granted
MACROCYCLIC INHIBITORS OF THE PD-1/PD-L1 AND CD80(B7-1)/PD-L1 PROTEIN/PROTEIN INTERACTIONS	11 Nov 2016	28 Apr 2017	Accepted

International Patent Classification (51): A61K 38/12, A61K 38/10, C07K 7/08, C07K 7/56, G01N 33/68, A61K 39/39, G01N 33/574

Convention Priority :

Country	Priority Date	Priority Number
United States of America	15 Mar 2013	61/794,589
United States of America	10 Mar 2014	14/201,977
United States of America	19 Dec 2013	61/918,184

Inventor(s):

YEUNG, Kap-Sun	Physical : C/o Bristol-Myers Squibb Company, 5 Research Parkway, Wallingford, Connecticut 06492, US
BOY, Kenneth M.	Physical : c/o Bristol-Myers Squibb Company 5 Research Parkway Wallingford, Connecticut 06492, US
SUN, Li-Qiang	Physical : c/o Bristol-Myers Squibb Company 5 Research Parkway Wallingford, Connecticut 06492, US
MULL, Eric	Physical : c/o Bristol-Myers Squibb Company 5 Research Parkway Wallingford, Connecticut 06492, US
GILLIS, Eric P.	Physical : c/o Bristol-Myers Squibb Company 5 Research Parkway Wallingford, Connecticut 06492, US
BOWSHER, Michael S.	Physical : c/o Bristol-Myers Squibb Company 5 Research Parkway Wallingford, Connecticut 06492, US
SCOLA, Paul Michael	Physical : c/o Bristol-Myers Squibb Company 5 Research Parkway Wallingford, Connecticut 06492, US
MILLER, Michael Matthew	Physical : c/o Bristol-Myers Squibb Company, Route 206 and Province Line Road, Princeton, New Jersey 08543, US
MAPELLI, Claudio	Physical : c/o Bristol-Myers Squibb Company , Route 206 and Province Line Road , Princeton , New Jersey 08543, US
ALLEN, Martin Patrick	Physical : c/o Bristol-Myers Squibb Company , Route 206 and Province Line Road , Princeton , New Jersey 08543, US
LANGLEY, David R.	Physical : c/o Bristol-Myers Squibb Company , 5 Research Parkway, Wallingford, Connecticut 06492, US
POIRIER, Maude A.	Physical : c/o Bristol-Myers Squibb Company , Route 206 and Province Line Road , Princeton , New Jersey 08543, US
SANGHVI, Nishith	Physical : c/o Bristol-Myers Squibb Company , Route 206 and Province Line Road , Princeton , New Jersey 08543, US
TENNEY, Daniel J.	Physical : c/o Bristol-Myers Squibb Company , 5 Research Parkway, Wallingford, Connecticut 06492, US
ZHU, Juliang	Physical : c/o Bristol-Myers Squibb Company , 5 Research Parkway, Wallingford, Connecticut 06492, US

REID, Patrick C.	Physical : 1-17-10 Eifukucho, Suginami-Ku, Tokyo 168-0064, JP
------------------	---

Agent :

AJ PARK	Postal : DX SX10007, Wellington, NZ Postal : PO Box 949, Wellington 6140, NZ Physical : Aon Centre, Level 22, 1 Willis Street, Wellington 6011, NZ Service : Aon Centre, Level 22, 1 Willis Street, Wellington 6011, NZ Email Address: casedataupdates@ajpark.com
---------	---

Applicant(s) :

BRISTOL-MYERS SQUIBB COMPANY	Physical : Route 206 and Province Line Road, Princeton New Jersey 08543-4000, US
------------------------------	--

Contact Details : AJ PARK, Aon Centre, Level 22, 1 Willis Street, Wellington 6011, NZ

History:

Type	Description	Journal	Published
Patent Renewal	Patent Renewed for 1 year until 13 Mar 2019 by CPA Global	1664	23 Feb 2018
Granted	Granted	1658	25 Aug 2017
Patent accepted	Patent Application Accepted	1654	28 Apr 2017
Application for National Patent under PCT	Application for National Patent under the PCT Submitted	1623	26 Sep 2014

Linked Cases: None

Patent Number (11): 730846

Submitted Date: 06 Apr 2017

Filing Date (22): 11 Sep 2014

Status: Filed

Application type: National Entry PCT

Postpone Acceptance period: 12

Technology group: Chemical

Next Maintenance Due Date: 11 Sep 2018

Expiry Date: 11 Sep 2034

National Phase Entry Date: 06 Apr 2017

Maintenance Date: 11 Sep 2018

Examination Requested: No

Expedited Examination Requested: No

GPPH Requested: No

Under Proceeding: No

Complete Specification Filing Date: 11 Sep 2014

OPI Date: 17 Mar 2016

PCT Publication Number: WO/2016/039749

PCT Application Number: PCT/US2014/055093

Application made under: Patents Act 2013

Granted as Patent of addition: No

Patent Title: MACROCYCLIC INHIBITORS OF THE PD-1/PD-L1 AND CD80 (B7-1)/PD-L1 PROTEIN/PROTEIN INTERACTIONS

Maori Conflict possible: No

Traditional knowledge: No

Abstract: The present disclosure provides novel macrocyclic peptides which inhibit the PD-1/PD-L1 and PD-L1/CD80 protein/protein interaction, and thus are useful for the amelioration of various diseases, including cancer and infectious diseases.

Patent Specifications:

Title	Filing Date	Publication Date	Status
MACROCYCLIC INHIBITORS OF THE PD-1/PD-L1 AND CD80 (B7-1)/PD-L1 PROTEIN/PROTEIN INTERACTIONS	06 Apr 2017	28 Apr 2017	Proposed

International Patent Classification (51): A61K 38/10, C07K 7/08, G01N 33/574

Convention Priority : None

Inventor(s):

SUN, Li-Qiang	Physical : c/o Bristol-Myers Squibb Company 5 Research Parkway Wallingford, Connecticut 06492, US
MULL, Eric	Physical : c/o Bristol-Myers Squibb Company 5 Research Parkway Wallingford, Connecticut 06492, US
GILLIS, Eric P.	Physical : c/o Bristol-Myers Squibb Company 5 Research Parkway Wallingford, Connecticut 06492, US
BOWSHER, Michael S.	Physical : c/o Bristol-Myers Squibb Company 5 Research Parkway Wallingford, Connecticut 06492, US
SCOLA, Paul Michael	Physical : c/o Bristol-Myers Squibb Company 5 Research Parkway Wallingford, Connecticut 06492, US
MILLER, Michael Matthew	Physical : c/o Bristol-Myers Squibb Company Route 206 and Province Line Road Princeton, New Jersey 08543, US
MAPELLI, Claudio	Physical : 465 Briggs Road Langhorne, PA 19047, US
ALLEN, Martin Patrick	Physical : c/o Bristol-Myers Squibb Company Route 206 and Province Line Road Princeton, New Jersey 08543, US

LANGLEY, David R.	Physical : c/o Bristol-Myers Squibb Company 5 Research Parkway Wallingford, Connecticut 06492, US
POIRIER, Maude A.	Physical : c/o Bristol-Myers Squibb Company Route 206 and Province Line Road Princeton, New Jersey 08543, US
SANGHVI, Nishith	Physical : 3 Kershaw Court Bridgewater, New Jersey 08807, US
TENNEY, Daniel J.	Physical : c/o Bristol-Myers Squibb Company 5 Research Parkway Wallingford, Connecticut 06492, US
YEUNG, Kap-Sun	Physical : c/o Bristol-Myers Squibb Company 5 Research Parkway Wallingford, Connecticut 06492, US
ZHU, Juliang	Physical : 22 Windsor Road East North Haven, CT 06473, US
GILLMAN, Kevin W.	Physical : c/o Bristol-Myers Squibb Company 5 Research Parkway Wallingford, Connecticut 06492, US
ZHAO, Qian	Physical : 93 Hintz Drive Wallingford, CT 06492, US
GRANT-YOUNG, Katharine A.	Physical : 19 Northwood Road Madison, CT 06443, US
CORNELIUS, Lyndon A.M.	Physical : c/o Bristol-Myers Squibb Company Route 206 and Province Line Road Princeton, New Jersey 08543, US

Agent :

AJ PARK	Postal : DX SX10007, Wellington, NZ Postal : PO Box 949, Wellington 6140, NZ Physical : Aon Centre, Level 22, 1 Willis Street, Wellington 6011, NZ Service : Aon Centre, Level 22, 1 Willis Street, Wellington 6011, NZ Email Address: casedataupdates@ajpark.com
---------	---

Applicant(s) :

BRISTOL-MYERS SQUIBB COMPANY	Physical : Route 206 and Province Line Road, Princeton New Jersey 08543-4000, US
------------------------------	--

Contact Details : AJ PARK, Aon Centre, Level 22, 1 Willis Street, Wellington 6011, NZ

History:

Type	Description	Journal	Published
Maintenance Reminder Sent	Maintenance Reminder Sent		11 Jun 2018
Application for National Patent enters National Phase	Application under the PCT enters national Phase		07 Apr 2017
Application for National Patent under PCT	Application for National Patent under the PCT Submitted	1654	28 Apr 2017

Linked Cases: None

Patent Number (11): 731684

Submitted Date: 08 May 2017

Filing Date (22): 07 Oct 2015

Status: Filed

Application type: National Entry PCT

Postpone Acceptance period: 12

Technology group: Chemical

Next Maintenance Due Date: 07 Oct 2019

Expiry Date: 07 Oct 2035

National Phase Entry Date: 08 May 2017

Maintenance Date: 07 Oct 2019

Examination Requested: No

Expedited Examination Requested: No

GPPH Requested: No

Under Proceeding: No

Complete Specification Filing Date: 07 Oct 2015

OPI Date: 14 Apr 2016

PCT Publication Number: WO/2016/057624

PCT Application Number: PCT/US2015/054407

Application made under: Patents Act 2013

Granted as Patent of addition: No

Patent Title: IMMUNOMODULATORS

Maori Conflict possible: No

Traditional knowledge: No

Abstract: The present disclosure provides novel macrocyclic peptides which inhibit the PD-1/PD-L1 and PD-L1/CD80 protein/protein interaction, and thus are useful for the amelioration of various diseases, including cancer and infectious diseases.

Patent Specifications:

Title	Filing Date	Publication Date	Status
IMMUNOMODULATORS	08 May 2017	26 May 2017	Proposed

International Patent Classification (51): C07K 7/52, C07K 7/56, A61K 38/12, G01N 33/68

Convention Priority :

Country	Priority Date	Priority Number
United States of America	10 Oct 2014	62/062,240

Inventor(s):

SUN, Li-Qiang	Physical : c/o Bristol-Myers Squibb Company 5 Research Parkway Wallingford, Connecticut 06492, US
MULL, Eric	Physical : c/o Bristol-Myers Squibb Company 5 Research Parkway Wallingford, Connecticut 06492, US
GILLIS, Eric P.	Physical : c/o Bristol-Myers Squibb Company 5 Research Parkway Wallingford, Connecticut 06492, US
SCOLA, Paul Michael	Physical : c/o Bristol-Myers Squibb Company 5 Research Parkway Wallingford, Connecticut 06492, US
ZHAO, Qian	Physical : 93 Hintz Drive, Wallingford, , Connecticut 06492, US

Agent :

AJ PARK	Postal : DX SX10007, Wellington, NZ Postal : PO Box 949, Wellington 6140, NZ Physical : Aon Centre, Level 22, 1 Willis Street, Wellington 6011, NZ Service : Aon Centre, Level 22, 1 Willis Street, Wellington 6011, NZ
---------	--

Applicant(s) :BRISTOL-MYERS SQUIBB
COMPANYPhysical : Route 206 and Province Line Road, Princeton New Jersey 08543-4000,
US**Contact Details :** AJ PARK, Aon Centre, Level 22, 1 Willis Street, Wellington 6011, NZ**History:**

Type	Description	Journal	Published
Application for National Patent enters National Phase	Application under the PCT enters national Phase		09 May 2017
Application for National Patent under PCT	Application for National Patent under the PCT Submitted	1655	26 May 2017

Linked Cases: None

This search facility provides information from the intellectual property registers administered and maintained by IPONZ. Whilst IPONZ takes all reasonable care in the provision of its services, IPONZ and the Ministry of Business, Innovation & Employment do not accept any responsibility or liability for any action taken in reliance on this information or for any error, inadequacy, deficiency or flaw in or omission from the information provided. This site is not intended to be a comprehensive or complete source of intellectual property information. To obtain further assistance on the use of this Internet site please contact us.